lomustine has been researched along with Lymphoma, T-Cell in 8 studies
Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 8.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| " The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice." | 8.12 | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 7.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| "Lomustine, vincristine, procarbazine and prednisolone (LOPP) chemotherapy has been suggested to be an effective treatment for dogs with naïve non-indolent T-cell lymphoma (TCL)." | 4.12 | Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy. ( Blaxill, J; Buzzacott, P; Finlay, J, 2022) |
| " The objective of the present study was to investigate if a shorter protocol combined with an oral lomustine maintenance treatment (3 × in 8 weeks) would present an acceptable result, both for B- and T-cell lymphomas, and for the different types of lymphomas normally encountered in private veterinary practice." | 4.12 | Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma. ( Eberle, N; Limmer, S; Nerschbach, V; Simon Betz, D; Teske, E, 2022) |
| "Multi-agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first-line chemotherapy to treatment-naïve canine lymphoma patients with measurable, high grade T-cell lymphoma (HGTCL)." | 3.91 | A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017). ( Baines, S; Elliott, J, 2019) |
| "The aim of this study was to describe the use of a lomustine (CCNU), vincristine, procarbazine and prednisolone (LOPP) protocol used for treatment of chemotherapy naive T-cell lymphoma patients and to describe the response rate, toxicity and disease-free interval compared historically to CHOP chemotherapy." | 3.88 | LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma. ( Brown, PM; Langova, V; Nguyen, S; Tzannes, S; White, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Blaxill, J | 1 |
| Buzzacott, P | 1 |
| Finlay, J | 1 |
| Limmer, S | 2 |
| Nerschbach, V | 2 |
| Eberle, N | 2 |
| Teske, E | 2 |
| Simon Betz, D | 2 |
| Purzycka, K | 1 |
| Peters, LM | 1 |
| Desmas, I | 1 |
| Davies, O | 1 |
| Chang, YM | 1 |
| Lara-Garcia, A | 1 |
| Brown, PM | 1 |
| Tzannes, S | 1 |
| Nguyen, S | 1 |
| White, J | 1 |
| Langova, V | 1 |
| Morgan, E | 1 |
| O'Connell, K | 1 |
| Thomson, M | 1 |
| Griffin, A | 1 |
| Elliott, J | 1 |
| Baines, S | 1 |
| Gong, Y | 1 |
| Liang, R | 1 |
| Chiu, E | 1 |
| Chan, TK | 1 |
| Todd, D | 1 |
| Loke, SL | 1 |
1 trial available for lomustine and Lymphoma, T-Cell
| Article | Year |
|---|---|
Radiotherapy of midline malignant reticulosis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Lomustine | 1995 |
7 other studies available for lomustine and Lymphoma, T-Cell
| Article | Year |
|---|---|
Prognostic indicators for naïve canine non-indolent T-cell lymphoma treated with combination lomustine, vincristine, procarbazine and prednisolone chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Hypercalcemia; Lomustin | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Efficacy and tolerability of a 12-week combination chemotherapy followed by lomustine consolidation treatment in canine B- and T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lomustine; Lymphoma; Ly | 2022 |
Clinicopathological characteristics and prognostic factors for canine multicentric non-indolent T-cell lymphoma: 107 cases.
Topics: Animals; Antineoplastic Agents, Alkylating; Disease Progression; Dog Diseases; Dogs; Lomustine; Lymp | 2020 |
LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lomustine; Lymp | 2018 |
Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dog Diseases; Dogs; | 2018 |
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Horm | 2019 |
Direct comparison of peripheral T-cell lymphomas with their B-cell counterpart.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; China; Cyclophosphamide; Dexamethasone; D | 1991 |